 Connection
Yuya Hirasawa to Female
This is a "connection" page, showing publications Yuya Hirasawa has written about Female.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.171 |
|
|
|
-
Hirasawa Y, Isobe J, Hosonuma M, Tsurui T, Baba Y, Funayama E, Tajima K, Murayama M, Narikawa Y, Toyoda H, Shida M, Sasaki A, Maruyama Y, Amari Y, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Sambe T, Uchida N, Wada S, Kobayashi S, Kiuchi Y, Kuramasu A, Yoshimura K, Tsunoda T. Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors. Front Immunol. 2025; 16:1528521.
Score: 0.032
-
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Hoffman RM, Tsunoda T. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment. Anticancer Res. 2024 Aug; 44(8):3397-3407.
Score: 0.031
-
Ariizumi H, Shimazui M, Ogawa C, Kaneki M, Saito N, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Hirasawa Y, Shimokawa M, Ohkuma R, Kubota Y, Horiike A, Wada S, Yoshimura K, Murakami K, Tsunoda T. Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study. Front Immunol. 2025; 16:1640603.
Score: 0.008
-
Shimizu T, Ohkuma R, Homma M, Nakayama S, Sasaki Y, Muto S, Ieguchi K, Watanabe M, Taguchi A, Takayanagi D, Wada Y, Horiike A, Kubota Y, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Mura E, Yoshimura K, Tsuji M, Kiuchi Y, Suzuki H, Yamochi T. Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression. Front Immunol. 2025; 16:1528594.
Score: 0.008
-
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunol Immunother. 2025 Aug 19; 74(9):289.
Score: 0.008
-
Yamashita T, Fujimasa K, Otsuka K, Saito A, Kohmoto M, Motegi K, Ariyoshi T, Goto S, Yamochi T, Takimoto M, Hirasawa Y, Kubota Y, Yoshimura K, Tsunoda T, Murakami M, Aoki T. Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma. Anticancer Res. 2025 May; 45(5):2051-2058.
Score: 0.008
-
Ishiguro T, Takeda K, Takayanagi D, Mura E, Suzuki R, Tsurui T, Iriguchi N, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Izumizaki M, Wada S, Yoshimura K, Hoffman RM, Tsunoda T. Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors. Cancer Genomics Proteomics. 2025 Jan-Feb; 22(1):1-12.
Score: 0.008
-
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Sci Rep. 2024 05 17; 14(1):11325.
Score: 0.008
-
Hamada K, Yoshimura K, Oshinomi K, Hirasawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsui H, Ishiguro T, Sambe T, Ishida H, Horiike A, Wada S, Iwamoto S, Uchida N, Ogawa Y, Kobayashi S, Tsunoda T. A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report. Medicine (Baltimore). 2022 Jan 14; 101(2):e28339.
Score: 0.006
-
Hamada K, Yoshimura K, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsukuma S, Ishiguro T, Sambe T, Horiike A, Kuramasu A, Wada S, Tsurutani J, Inoue E, Uchida N, Kiuchi Y, Kobayashi S, Hoffman RM, Tsunoda T. Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy. Anticancer Res. 2021 Oct; 41(10):4985-4993.
Score: 0.006
-
Tsuboya A, Kubota Y, Ishida H, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Sasaki Y, Matsumoto N, Kondo Y, Tomoda Y, Kusuhara H, Fujita KI. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Cancer Chemother Pharmacol. 2021 09; 88(3):543-553.
Score: 0.006
-
Miyazaki K, Hirasawa Y, Aga M, Aiko N, Hamakawa Y, Taniguchi Y, Misumi Y, Agemi Y, Shimokawa T, Hayashi H, Naoki K, Okamoto H. Examination of endobronchial ultrasound-guided transbronchial needle aspiration using a puncture needle with a side trap. Sci Rep. 2021 05 07; 11(1):9789.
Score: 0.006
-
Ohkuma R, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Aoki T, Murakami M, Kobayashi S, Tsunoda T, Wada S. The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer. Pancreas. 2021 02 01; 50(2):167-175.
Score: 0.006
-
Ohkuma R, Yada E, Ishikawa S, Komura D, Kubota Y, Hamada K, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Kobayashi S, Tsunoda T, Wada S. High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer. Int J Oncol. 2021 01; 58(1):57-69.
Score: 0.006
-
Ando K, Hamada K, Shida M, Ohkuma R, Kubota Y, Horiike A, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2021 Feb; 70(2):337-348.
Score: 0.006
-
Matsumoto N, Kubota Y, Ishida H, Sekido M, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Ikusue T, Kobayashi K, Hisamatsu A, Toshima H, Shimada K, Fujita KI. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer Chemother Pharmacol. 2020 06; 85(6):1119-1128.
Score: 0.006
-
Ohkuma R, Yada E, Ishikawa S, Komura D, Kubota Y, Hamada K, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Kobayashi S, Tsunoda T, Wada S. High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer. Oncol Rep. 2020 07; 44(1):252-262.
Score: 0.006
-
Ando K, Hamada K, Watanabe M, Ohkuma R, Shida M, Onoue R, Kubota Y, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors. Anticancer Res. 2019 Sep; 39(9):5195-5201.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|